Content · healthcare · emerging marketsJul 202610 min read391 words

B2B webinars: a case study playbook for healthcare and life sciences in emerging markets

The anatomy of a B2B webinars engagement that worked — what we tried, what we killed, and what we would repeat. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install B2B webinars has to be shaped to that reality from day one.

Names removed, numbers preserved. This is a real B2B webinars engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.

Week one: diagnosis. The stated problem was "not enough leads". The actual problem was measuring registrants instead of pipeline, which had been masked by inbound velocity that peaked two quarters earlier.

Weeks two to three: rebuild the target list from scratch and re-cut the trigger. B2B webinars works when the questions in the chat are the sharpest ICP research you can buy; the client had drifted away from that first principle.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. B2B webinars is only useful here when it is pointed at both constraints at once.

Weeks four to six: live at 20% of previous volume, quality bar raised. Opportunities created within 30 days of the session moved every week, though absolute numbers stayed modest.

Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.

What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.

The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.

Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing B2B webinars deliberately for this market rather than importing a playbook designed for somewhere else.

B2B webinarswebinar strategyvirtual eventsB2B webinars case studyB2B webinars playbookB2B webinars for healthcare and life sciencesB2B webinars in emerging marketshealthcare and life sciences growth in emerging markets

Frequently asked questions

Content · healthcare · emerging markets — answered

Does B2B webinars work for healthcare and life sciences in emerging markets?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
How long until the case study company saw results?
The metric moved in week four; the absolute number caught up around week ten.
What did the client stop doing?
Running old tools on autopilot and confusing volume with progress.
What did the client keep doing?
The Monday plan, the Friday review, and the weekly opportunities created within 30 days of the session readout.
Is this case study repeatable?
The process is repeatable; the numbers depend on category, team, and starting point.
What is the emerging markets-specific pitfall when running B2B webinars for healthcare?
Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.

Growth Broker editorial

Filed under content · healthcare · emerging markets

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call